Monument Capital Management lessened its stake in Eli Lilly And Co (NYSE:LLY) by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,460 shares of the company’s stock after selling 480 shares during the quarter. Monument Capital Management’s holdings in Eli Lilly And Co were worth $1,841,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Enterprise Trust & Investment Co purchased a new stake in shares of Eli Lilly And Co during the third quarter valued at approximately $27,000. Garrett Wealth Advisory Group LLC purchased a new stake in shares of Eli Lilly And Co during the third quarter valued at approximately $29,000. Candriam Luxembourg S.C.A. increased its position in shares of Eli Lilly And Co by 47.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock valued at $30,000 after acquiring an additional 87,250 shares during the last quarter. Prestige Wealth Management Group LLC purchased a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $34,000. Finally, Manchester Financial Inc. purchased a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $40,000. Institutional investors own 76.75% of the company’s stock.
In other news, SVP Alfonso G. Zulueta sold 4,500 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $117.00, for a total value of $526,500.00. Following the completion of the transaction, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $3,955,302. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $116.37, for a total value of $24,437,700.00. The disclosure for this sale can be found here. Insiders sold 243,452 shares of company stock valued at $28,252,925 over the last three months. Company insiders own 0.11% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $1.48 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts expect that Eli Lilly And Co will post 5.73 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a yield of 2.39%. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.
A number of brokerages recently commented on LLY. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Bank of America began coverage on Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 price target for the company. Finally, UBS Group decreased their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $127.69.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Capital Gains
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.